Core Viewpoint - A class action lawsuit has been filed against Dow Inc. for allegedly failing to disclose critical information regarding its business prospects, leading to significant financial losses for shareholders [1][2]. Allegations - The lawsuit claims that Dow Inc. overstated its ability to handle macroeconomic challenges and maintain financial flexibility for dividends, while understating the negative impacts of competitive pressures, declining global sales, and product oversupply [2]. Stock Performance - On June 23, 2025, BMO downgraded Dow's stock rating from "Market Perform" to "Underperform," reducing the price target from $29.00 to $22.00, which resulted in a 3.21% drop in stock price to $26.87 [3]. - Following disappointing Q2 2025 financial results, where Dow reported a non-GAAP loss per share of $0.42 and net sales of $10.1 billion (a 7.3% year-over-year decline), the stock price fell by 17.45% to close at $25.07 on July 24, 2025 [4]. Financial Results - Dow's Q2 2025 results significantly missed analyst expectations, with a loss per share much larger than the anticipated $0.17 to $0.18, and net sales falling short by $130 million [4]. Dividend Cut - On the same day as the disappointing financial results, Dow announced a 50% cut to its dividend, further impacting investor confidence and stock price [4].

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who acquired Lockheed Martin Corporation (LMT) securities between January 23, 2024, and July 21, 2025, alleging that the company misled investors regarding its business prospects [1][2]. Allegations - The complaint states that Lockheed Martin failed to disclose several critical issues, including: - Lack of efficient internal controls related to risk-adjusted contracts and profit booking rates [2] - Absence of effective procedures for comprehensive reviews of program requirements, technical complexities, schedules, and risks [2] - Overstatement of the company's ability to meet contract commitments regarding cost, quality, and schedule [2] - Likelihood of reporting significant losses as a result of these issues [2] Financial Impact - On July 22, 2025, Lockheed Martin disclosed an additional $1.6 billion in pre-tax losses on classified programs, which included: - $950 million in losses from the Aeronautics Classified program - $570 million in losses from the Canadian Maritime Helicopter Program - $95 million charge related to the Turkish Utility Helicopter Program - Following this announcement, the company's share price dropped by $49.79, or over 10%, closing at $410.74 on the same day [3]. Class Action Participation - Shareholders interested in serving as lead plaintiffs must submit their papers by September 26, 2025. Participation in the case is not required to be eligible for recovery [4]. Company Background - Robbins LLP is recognized for its leadership in shareholder rights litigation, focusing on helping shareholders recover losses and improve corporate governance since 2002 [5].

Core Viewpoint - A class action lawsuit has been filed against LifeMD, Inc. for allegedly misleading investors about its business prospects and competitive position during a specified period in 2025 [1][2]. Allegations - The complaint alleges that LifeMD's management materially overstated the company's competitive position and recklessly raised its 2025 guidance without properly accounting for rising customer acquisition costs in its RexMD segment and related to obesity treatment drugs [2]. - The statements made by the defendants regarding LifeMD's business operations and prospects were claimed to be materially false and misleading [2]. Financial Impact - Following the announcement of its second quarter 2025 results, which included a revision of full-year guidance due to "temporary challenges" in the RexMD business, LifeMD's stock price dropped by $5.31, or 44.8%, closing at $6.53 on August 6, 2025 [3]. Class Action Participation - Shareholders interested in participating as lead plaintiffs in the class action must file their papers by October 27, 2025, although they can remain absent class members without taking action [4].

Group 1 - A class action has been filed on behalf of investors who purchased Replimune Group, Inc. (NASDAQ: REPL) securities between November 22, 2024, and July 21, 2025 [1] - Robbins LLP is investigating allegations that Replimune Group, Inc. misled investors regarding the viability of its IGNYTE trial, claiming that the company overstated the trial's prospects and failed to disclose material issues [2] - On July 22, 2025, Replimune announced it received a complete response letter (CRL) from the FDA, indicating that the IGNYTE trial was not considered adequate, leading to a significant stock price drop of $9.52 per share, or 77.24%, closing at $2.80 per share [3] Group 2 - Shareholders interested in participating as lead plaintiffs must file their papers with the court by September 22, 2025, and can remain absent class members if they choose not to participate [4] - Robbins LLP operates on a contingency fee basis, meaning shareholders pay no fees or expenses [5] - The firm has been dedicated to helping shareholders recover losses and improve corporate governance since 2002 [5]

Core Viewpoint - A class action has been filed against Capricor Therapeutics, Inc. for allegedly misleading investors regarding the viability of its lead product candidate, deramiocel, for treating Duchenne muscular dystrophy (DMD) [1][2]. Group 1: Company Overview - Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing cell and exosome-based therapeutics for DMD and other diseases with unmet medical needs in the U.S. [1] - The company's lead product candidate is deramiocel, which consists of allogeneic cardiosphere-derived cells [1]. Group 2: Allegations and Legal Action - Robbins LLP is investigating allegations that Capricor misled investors about deramiocel's potential for first approval for DMD cardiomyopathy while concealing adverse safety and efficacy data from its Phase 2 HOPE-2 trial [2]. - The complaint states that the misleading information led to shareholders purchasing Capricor's securities at artificially inflated prices [2]. Group 3: Stock Price Impact - On July 11, 2025, Capricor announced it received a Complete Response Letter (CRL) from the FDA, denying its Biologics License Application due to insufficient evidence of effectiveness and the need for additional clinical data [3]. - Following the announcement, Capricor's stock price fell from $11.40 per share on July 10, 2025, to $7.64 per share on July 11, 2025 [3].

Group 1 - The core issue involves a class action lawsuit against Spectrum Pharmaceuticals, alleging false or misleading statements regarding its Pinnacle Study related to the drug poziotinib for lung cancer treatment [2] - The Lead Plaintiff appointment process for the class action has reopened, allowing shareholders who purchased shares between March 17, 2022, and September 22, 2022, to file their papers by September 24, 2025 [1][3] - Spectrum Pharmaceuticals focuses on acquiring, developing, and commercializing novel and targeted oncology therapies [1] Group 2 - The lawsuit claims that the company misrepresented information that could affect investor decisions, particularly concerning the clinical trial results of poziotinib [2] - Robbins LLP, the law firm involved, emphasizes that shareholders do not need to participate in the case to be eligible for recovery [3] - The firm operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless there is a recovery [4]

Core Viewpoint - A class action lawsuit has been filed against PubMatic, Inc. for allegedly misleading investors about its business prospects during a specific period, leading to a significant drop in stock price following the release of disappointing financial results [1][2][3]. Company Overview - PubMatic, Inc. is a technology company that facilitates real-time programmatic advertising transactions for advertisers, agencies, and demand-side platforms (DSPs) [1]. Allegations - The lawsuit claims that during the class period, PubMatic failed to disclose critical information regarding a major DSP buyer shifting clients to a new platform, which impacted ad spend and revenue [2]. - The complaint highlights that on August 11, 2025, PubMatic reported a reduction in ad spend from one of its top DSP partners, which was attributed to the shift in inventory evaluation methods by the DSP [3]. Financial Impact - Following the announcement of the second quarter 2025 financial results, PubMatic's stock price fell by $2.23, or 21.1%, closing at $8.34 per share on August 12, 2025 [3]. Legal Proceedings - Shareholders interested in participating in the class action must submit their papers by October 20, 2025, to serve as lead plaintiff, representing the interests of other class members [4].

Core Viewpoint - A class action lawsuit has been filed against Snap Inc. for allegedly misleading investors about its business prospects, particularly regarding advertising revenue and growth expectations during the specified period [1][2]. Allegations - The complaint claims that Snap's management created a false impression of having reliable information about expected advertising revenue while downplaying macroeconomic instability [2]. - Snap's optimistic reports on advertising growth were found to be misleading, as they were overly reliant on the company's execution capabilities, which were already faltering [2]. Financial Results and Stock Impact - On August 5, 2025, Snap reported a slowdown in advertising revenue growth, attributing it to issues with its ad platform and external factors like the timing of Ramadan [3]. - Following this announcement, Snap's stock price dropped from $9.39 per share to $7.78 per share, marking a decline of over 17% [3]. Class Action Participation - Shareholders may be eligible to participate in the class action against Snap Inc. and can contact Robbins LLP for more information [3]. - Individuals interested in serving as lead plaintiffs are encouraged to reach out, although participation is not required for recovery eligibility [3]. About Robbins LLP - Robbins LLP is a recognized leader in shareholder rights litigation, focusing on helping shareholders recover losses and improve corporate governance since 2002 [4].

Group 1 - A class action has been filed against Snap Inc. on behalf of investors who acquired its securities between April 29, 2025, and August 5, 2025 [1] - The allegations state that Snap misled investors about its advertising revenue and growth prospects, creating a false impression of reliable information while downplaying macroeconomic instability [2] - On August 5, 2025, Snap reported a slowdown in advertising revenue growth, attributing it to issues with its ad platform and other factors, leading to a stock price decline of over 17% from $9.39 to $7.78 per share [3] Group 2 - Robbins LLP is investigating the claims and encourages shareholders to participate in the class action, with options to serve as lead plaintiff or remain an absent class member [3] - The representation in the class action is on a contingency fee basis, meaning shareholders will not incur fees or expenses [4]

Core Viewpoint - A class action lawsuit has been filed against PubMatic, Inc. for allegedly misleading investors about its business prospects during a specific period, leading to a significant drop in stock price following the release of disappointing financial results [1][2][3]. Company Overview - PubMatic, Inc. is a technology company that facilitates real-time programmatic advertising transactions for advertisers, agencies, and demand-side platforms (DSPs) [1]. Allegations - The lawsuit claims that during the class period, PubMatic failed to disclose critical information regarding a top DSP buyer shifting clients to a new platform, which affected ad spend and revenue [2]. - The complaint highlights that on August 11, 2025, PubMatic reported a reduction in ad spend from one of its top DSP partners, which was attributed to the shift in client evaluation methods [3]. Financial Impact - Following the announcement of the second quarter 2025 financial results, PubMatic's stock price fell by $2.23, or 21.1%, closing at $8.34 per share on August 12, 2025 [3]. Legal Proceedings - Shareholders interested in participating in the class action must submit their papers by October 20, 2025, to serve as lead plaintiff [4]. - The lead plaintiff will represent other class members in directing the litigation, but participation is not required for recovery [4]. Firm Background - Robbins LLP is noted for its focus on shareholder rights litigation, aiming to help shareholders recover losses and improve corporate governance since 2002 [5].